FDA approves Adcetris for first-line classical Hodgkin's lymphoma

FDA approved an sBLA from Seattle Genetics Inc. (NASDAQ:SGEN) for Adcetris brentuximab vedotin (SGN-35) in combination with chemotherapy to treat adults with previously untreated stage

Read the full 253 word article

User Sign In